All News

RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Jack Cush, MD

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
audience learn

Day 4 Report from ACR21

Jack Cush, MD

My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.

Read Article
EULAR19.abstract.jpg (keep)

ACR21 – Day 3 Report

Jack Cush, MD

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.

Read Article
Cush ACR learning computer online

Day 2 Report from ACR21

Jack Cush, MD

This report highlights the VITAL trial; the ORAL Surveillance Study; and the Microbiome study of monozygotic psoriasis patients.

Read Article
ACR Best

ACR21 Best Abstracts - Day 2

Jack Cush, MD

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).

Read Article
acr_session2.jpeg

Opening Day Report

Jack Cush, MD

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).

Read Article
JAK Safety -- The Lowdown on Infection https://t.co/Mi6EDqP7RE https://t.co/ZVZaXHGHIk

Links:

Dr. John Cush RheumNow ( View Tweet)
Herpes Zoster and Rheumatoid Arthritis: Dr. Akhil Sood ( @AkhilSoodMD) reviews abstract #0981 presented at the #ACR21 annual meeting. https://t.co/M95XQOBWVf https://t.co/X9vaAEAias

Links:

Dr. John Cush RheumNow ( View Tweet)
Infections in ORAL Surveillance: Drs. Kevin Winthrop and Jonathan Kay https://t.co/GtMtUh33QE https://t.co/yjJngF25Y4

Links:

Dr. John Cush RheumNow ( View Tweet)
Did you know?🤔Immune #aging: 🔖Begins at 20y and accelerates at 50y 🔖Species-specific 🔖The older immune system is restructured (keep that in mind when diagnosing or treating these pts) 🔖Accelerated w/ chemotx, chronic infection etc. @RheumNow #ACR21 https://t.co/bgbN3VKMCw
sheila RHEUMarampa ( View Tweet)
Infxn risk of 1st year on rituximab for mod to severe SLE vs standard-of-care 🔹Most common SoC Rx: MMF, Aza, and/or cyclophosphamide 🔹🚫significant diff 🔹RTX pts = ⬆️dz duration, ⬆️# of prior meds, ⬇️maintenance steroid dose https://t.co/AYQFXqlubl #ACR21 Abst1288 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

Knowledge Bowl at #ACR21 ⭐️In this triad seen in TB arthritis, one can see juxta-articular osteopenia, peripheral osseous erosions, and late joint space narrowing ➡️Phermister's triad @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

#volcosporin good ~lupus nephritis added to #MMF but underbelly - side effects like but ?less than #cyclosporin. #FDA update - ⬆️hypertension and nephrotoxicity, infection #ACR21 @RheumNow https://t.co/w5nLLSTlrB

Links:

Janet Pope Janetbirdope ( View Tweet)

#PJP prophylaxis debate at #lupus hub if on #prednisone + immune suppression. #SLE has ⤴️septra side effects. Don’t know right answer. NNT v NNH is unknown. I don’t use it in #SLE. @RheumNow #ACR21 8M212

Janet Pope Janetbirdope ( View Tweet)

A worthwhile point: despite historic concerns, in the modern era TNFi can used safely & well in HIV pts 18y follow-up, all pts high CD4 (their starting criteria: CD4>200, VL <60,000) no reported opportunistic infx good arthritis response #ACR21 ABST0965 @RheumNow @CCalabreseDO https://t.co/5pbRg63ubr
David Liew drdavidliew ( View Tweet)
HZV in pts w/ #rheumatic dse by Dr CCMok et al 🔸Prevalence rates of HZV infxn (per 100py): SLE 1.7, RA 0.64, other RDs 0.76 🔸RFs assoc'd w/1st HZV infection 📌#SLE dx, serum albumin, serum creatinine; ⬆lympho/neutro ratio, CYC & Prednisolone use @RheumNow #ACR21 abs0862 https://t.co/TXRmoBBDXK
sheila RHEUMarampa ( View Tweet)
Abst 0562 Ungprasert & colleagues examine hospitalization and resource utilization among patients with #AnkylosingSpondylitis - Prevalence is high - Infection was among the most common reasons for hospitalization (sepsis, pneumonia, UTI) #ACR21 @RheumNow https://t.co/UftoFllE1v
Akhil Sood MD AkhilSoodMD ( View Tweet)
Role of anti-CK antibodies: 👉⬆️susceptibility to severe mycobacterial dz & opportunistic infx (similar to HIV) 👉causes an indeterminate quantiferon (no response to mitogen) 👉initiated by infx➡️anti-Noc2 Ab➡️cross react with IFN➡️IFN-Ab 👉⬆️severity of #COVID19 #ACR21 1/2 https://t.co/5NHQpwQw6X
TheDaoIndex KDAO2011 ( View Tweet)
It is always difficult to distinguish infection and disease flares in autoinflammatory syndromes = 25 pt sJIA study at #ACR21 showing serum procalcitonin levels are useful when >0.95ng/ml @StillsDis_411 @rheumnow #abst0252

Bella Mehta bella_mehta ( View Tweet)

@jhrheumatology Dr. Petri at #ACR21 Great Debate. Safety issues with Voclosporin: 1) Nephrotoxicity 2) Infection 3) CV Risk Factors 4) Malignancy 5) Neurologic toxicity 6) Osteoporosis 7) Drug interactions 8) Deaths 9) Pregnancy contraindication @RheumNow https://t.co/wjluivmKNt
Eric Dein ericdeinmd ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×